SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN

1 . A suspension of metronidazole or a salt or ester derivative thereof, comprising metronidazole or a salt or ester derivative thereof; a hydrocolloid stabilizer, simethicone emulsion; sodium citrate, (dihydrate); a preservative, a thickening agent, a sweetener, and water.

2 . The suspension of claim 1 , wherein the hydrocolloid stabilizer is microcrystalline cellulose and/or carboxymethylcellulose sodium.

3 . The suspension of claim 1 , wherein the thickening agent is xanthan gum.

4 . The suspension of claim 1 , wherein the suspension comprises metronidazole benzoate.

5 . The suspension of claim 1 , wherein the sweetener is selected from the group consisting of ammonium glycyrrhizate, sucralose, and saccharin sodium.

6 . The suspension of claim 1 , wherein the preservative is sodium benzoate.

7 . The suspension of claim 1 , wherein the preservative is citric acid.

8 . The suspension of claim 1 , further comprising flavor grape 59.266/A.

9 . The suspension of claim 1 , wherein the pH of the formulation is between 3.6 and 4.6.

10 . The suspension of claim 1 , wherein the formulation retains homogeneity of less than +/−5% of assay for active pharmaceutical ingredient after at least 30 days.

11 . The suspension of claim 1 , wherein the suspension includes the following:

a. 0.05% (w/v) ammonium glycyrrhizate, (magnasweet 100);

b. 1.50% (w/v) Avicel RC591;

c. 0.50% (w/v) citric acid, (anhydrous);

d. 0.05% (w/v) flavor grape 59.266/A;

e. 0.03% (w/v) saccharin sodium;

f. 0.2% (w/v) simethicone emulsion, (30%);

g. 0.15% (w/v) sodium benzoate, NF;

h. 0.20% (w/v) sodium citrate, (dihydrate);

i. 0.10% (w/v) sucralose;

j. 0.10% (w/v) xanthan gum; and

k. purified water,

12 . The suspension of claim 1 , wherein the suspension includes the following:

a. 0.12% (w/v) citric acid, (anhydrous);

b. 0.0002% (w/v) D&C Yellow No. 10;

c. 0.000038% (w/v) FD&C Red No. 40;

d. 0.0500% (w/v) flavor grape 59.266/A;

e. 0.5000% (wv) hydroxyethyl cellulose;

f. 5.000% (w/v) propylene glycol;

g. 0.1500% (w/v) simethicone emulsion, (30%);

h. 0.1000% (w/v) sodium benzoate;

i. 0.2000% (w/v) sucralose;

j. purified water.

13 . A liquid diluent comprising: 0.03-0.08% (w/v) ammonium glycyrrhizate; 1.0-2.0% (w/v) Avicel RC591; 0.1-0.9% (w/v) citric acid; 0.01-0.10% (w/v) flavoring; 0.01-0.05% (w/v) saccharin sodium; 0.1-0.3% (w/v) simethicone emulsion; 0.1-0.2% (w/v) sodium benzoate; 0.1-0.3% (w/v) sodium citrate, (dihydrate); 0.05-0.2% (w/v) sucralose; 0.05-0.2% (w/v) xanthan gum; and purified water.

14 . The liquid diluent of claim 12 , comprising:

0.05% (w/v) ammonium glycyrrhizate, (magnasweet 100); 1.50% (w/v) Avicel RC591; 0.50% (w/v) citric acid, (anhydrous); 0.05% (w/v) flavor grape 59.266/A; 0.03% (w/v) saccharin sodium; 0.2% (w/v) simethicone emulsion, (30%); 0.15% (w/v) sodium benzoate; 0.20% (w/v) sodium citrate, (dihydrate); 0.10% (w/v) sucralose; 0.10% (w/v) xanthan gum; and purified water.

15 . A suspension of metronidazole, comprising a salt or ester derivative of metronidazole; simethicone emulsion; sodium bicarbonate; and sodium citrate, (dihydrate), wherein the suspension is stable for at least 30 days when stored at 2-8 degrees celsius.

16 . The suspension of claim 1 , wherein the suspension comprises a pH of no more than pH 4.6.

17 . The suspension of claim 1 , wherein the formulation retains homogeneity of less than +/−5% of assay for active pharmaceutical ingredient after at least 30 days.

18 . The suspension of claim 1 , wherein the formulation maintains homogeneity of the active pharmaceutical ingredient for at least 30 days after reconstitution.

19 - 28 . (canceled)

29 . A liquid diluent comprising: citric acid; flavoring; hydroxyethyl cellulose; simethicone emulsion; propylene glycol; sodium benzoate; sucralose; and purified water.